Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Bangor Savings Bank

Bangor Savings Bank cut its position in Bristol-Myers Squibb (NYSE:BMY) by 1.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 42,045 shares of the biopharmaceutical company’s stock after selling 698 shares during the period. Bangor Savings Bank’s holdings in Bristol-Myers Squibb were worth $2,378,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BMY. Lantz Financial LLC grew its holdings in shares of Bristol-Myers Squibb by 17.4% during the second quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 1,747 shares in the last quarter. Chris Bulman Inc purchased a new stake in Bristol-Myers Squibb during the 2nd quarter valued at about $48,000. Caprock Group LLC raised its holdings in Bristol-Myers Squibb by 56.0% in the 2nd quarter. Caprock Group LLC now owns 44,767 shares of the biopharmaceutical company’s stock valued at $1,859,000 after acquiring an additional 16,069 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Bristol-Myers Squibb by 29,957.4% during the 2nd quarter. Quest Partners LLC now owns 40,878 shares of the biopharmaceutical company’s stock worth $1,698,000 after purchasing an additional 40,742 shares during the last quarter. Finally, First Foundation Advisors grew its position in shares of Bristol-Myers Squibb by 73.0% in the second quarter. First Foundation Advisors now owns 5,656 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 2,386 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Up 0.2 %

NYSE BMY opened at $56.68 on Tuesday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The firm has a 50 day simple moving average of $57.22 and a 200-day simple moving average of $51.15. The firm has a market cap of $114.96 billion, a price-to-earnings ratio of -15.79, a PEG ratio of 15.20 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.00 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.38%. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, three have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $55.64.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.